Abstract: A device and method for detecting complications during an extracorporeal blood treatment are provided. During the dialysis treatment, the dialysance or clearance may be continuously determined at successive points in time based on a measured change in a physical or chemical characteristic quantity of the dialysis liquid, for example, the ion concentration of the dialysis liquid. In the event a significant change in the dialysance or clearance is established, the determination of the recirculation is may be effected based on a measured change in a physical or chemical characteristic quantity of the blood. When both a significant change in the determined dialysance as well as in the recirculation occurs, a complication is may be assumed with regard to a bad vessel access. Alternatively, a complication may be assumed with regard to the dialyzer.

Abstract: A method for determining the hematocrit and/or blood volume during an extracorporeal blood treatment with an extracorporeal blood circuit, in which blood is taken with a blood pump via an arterial cannula and an arterial flexible-tube line and blood is fed back via a venous flexible-tube line and a venous cannula. Pressure is measured in the extracorporeal blood circuit and a change in the hematocrit is determined from a change in the pressure. The respective relationship between hematocrit HKT or blood volume RBV and pressure P in the extracorporeal circuit is stored for various cannula diameters and various blood-flow values. The respective relationship for a given cannula diameter and blood flow is selected. The hematocrit and/or blood volume is determined taking account of the selected relationship.

Abstract: A method for determining the hemocrit and/or blood volume during an extracorporeal blood treatment with an extracorporeal blood circuit, in which blood is taken with a blood pump via an arterial cannula and an arterial flexible-tube line and blood is fed back via a venous flexible-tube line and a venous cannula. Pressure is measured in the extracorporeal blood circuit and a change in the hematocrit is determined from a change in the pressure. The respective relationship between hematocrit HKT or blood volume RBV and pressure P in the extracorporeal circuit is stored for various cannula diameters and various blood-flow values. The respective relationship for a given cannula diameter and blood flow is selected. The hematocrit and/or blood volume is determined taking account of the selected relationship.

Abstract: A device and method for increasing the safety of an extracorporeal blood treatment machine are based on monitoring transmembrane pressure. The transmembrane pressure measured by a measuring device during the treatment is compared with an upper limit transmembrane pressure L1 and a lower limit transmembrane pressure L2 which define a monitoring window. If the transmembrane pressure is outside this monitoring window, an alarm is triggered by an alarm device. The monitoring window is shifted as a function of the ultrafiltration rate. To determine the window limits, the transmembrane pressure is established after a change in the ultrafiltration rate is calculated. Thereafter, the window limits are determined on the basis of the expected transmembrane pressure.

Abstract: The present invention relates to liquid washing, cleaning, disinfecting bleaching compositions comprising amphiphilic copolymers which include structural units derived from

Abstract: Disclosed is a method of obtaining selectable transgenic stem cells of a vertebrate by transfecting a male germ cell with a transfection mixture comprising a nucleic acid construct containing a transcriptional unit of a stem cell-specific promoter, for example, a cyclin A1 promoter, operatively linked to a gene encoding a fluorescent or light-emitting reporter protein. The transfection mixture is a composition for transfection, in vivo or ex vivo, of a vertebrate's male germ cells, which comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell.

Abstract: Disclosed is a method of obtaining selectable transgenic stem cells of a vertebrate by transfecting a male germ cell with a transfection mixture comprising a nucleic acid construct containing a transcriptional unit of a stem cell-specific promoter, for example, a cyclin A1 promoter, operatively linked to a gene encoding a fluorescent or light-emitting reporter protein. The transfection mixture is a composition for transfection, in vivo or ex vivo, of a vertebrate's male germ cells, which comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell.